Patents by Inventor Cynthia A. Gill

Cynthia A. Gill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240043549
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: June 26, 2023
    Publication date: February 8, 2024
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Patent number: 11692040
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: July 4, 2023
    Assignee: ALS THERAPY DEVELOPMENT INSTITUTE
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Patent number: 11113772
    Abstract: An apparatus for activity networking, comprising: a memory coupled to at least one processor, the processor being configured to: transmit, to a server, a request to form a crew, the request including an indication of an activity associated with the crew, an indication of a time for performing the activity, and an indication of a number of available spots on the crew; receive from the server a message indicating that all spots on the crew are occupied by a plurality of users; and provide the plurality of users with a calendar appointment for the activity.
    Type: Grant
    Filed: February 28, 2016
    Date of Patent: September 7, 2021
    Inventor: Cynthia Gill
  • Publication number: 20210269538
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: May 17, 2021
    Publication date: September 2, 2021
    Applicant: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Patent number: 11014990
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: May 25, 2021
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Publication number: 20200277391
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: May 13, 2020
    Publication date: September 3, 2020
    Applicant: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Patent number: 10683356
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 16, 2020
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Publication number: 20190092868
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 28, 2019
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Patent number: 10106618
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: October 23, 2018
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Publication number: 20170342158
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 30, 2017
    Applicant: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Publication number: 20170249706
    Abstract: An apparatus for activity networking, comprising: a memory coupled to at least one processor, the processor being configured to: transmit, to a server, a request to form a crew, the request including an indication of an activity associated with the crew, an indication of a time for performing the activity, and an indication of a number of available spots on the crew; receive from the server a message indicating that all spots on the crew are occupied by a plurality of users; and provide the plurality of users with a calendar appointment for the activity.
    Type: Application
    Filed: February 28, 2016
    Publication date: August 31, 2017
    Inventor: Cynthia Gill, Esq